139 results about "Lipid accumulation" patented technology

The invention discloses a method for improving beef quality, an action mechanism and an experimental method, in a cattle body, vitamin A can activate the expression of EBF2 through an active metabolite RA of the vitamin A, and the EBF2 can inhibit the transcription process of CYP26B1 in a targeted manner to maintain the activity of a retinol signal channel, so that PPAR gamma and downstream lipid metabolism related genes thereof are activated, and the activity of the retinol signal channel is improved. Fatty acid transport and lipid accumulation in fat cells in the cattle muscle are promoted, fat deposition in the cattle muscle is promoted, and the beef quality is improved. By constructing the molecular network for regulating and controlling the formation of the fat in the cattle muscle, a complex regulation and control mechanism for controlling the fat deposition in the cattle muscle can be understood more deeply, a method for improving the beef quality based on regulating and controlling the vitamin A mediated key factor EBF2 is provided, and a new way is provided for improving the beef quality in a targeted manner.

The invention provides a hypoglycemic peptide which is prepared by taking bovine whey protein as a raw material and is stable in gastrointestinal digestion and absorption. In an in-vitro cell experiment, the peptide fragment can improve the uptake of insulin-resistant HepG2 hepatocytes and synthesize glycogen by using glucose, can promote intestinal endocrine cells NCI-H716 to secrete GLP-1, has a certain synergistic effect, and can further play the effects of promoting GLP-1 secretion and activating a GLP-1 receptor through combined use. An insulin resistance mouse model is constructed by utilizing high-fat diet, and the peptide fragment is adopted for intervention, so that the hypoglycemic peptide is further proved to have obvious effects on losing weight, reducing lipid accumulation and assisting in reducing blood fat, and meanwhile, the hypoglycemic peptide can be used for improving insulin resistance related symptoms. The milk peptide provided by the invention has gastrointestinal digestion stability and hypoglycemic activity, can be used as a functional milk base material for developing food, medicines or health care products with the effect of regulating blood sugar, and is wide in application prospect.

The invention discloses application of a lucid ganoderma extract combined with clostridium butyricum in preparation of fat-reducing food or medicine. The invention finds that the ganoderma lucidum extract is combined with clostridium butyricum for use, so that the weight gain of a mouse induced by high-fat diet can be obviously slowed down, the epididymal fat weight of the high-fat mouse is reduced, and the lipid accumulation in the liver and serum of the mouse is reduced; according to the present invention, with the application of the polypeptide, the fat cell size is reduced, the expression of the key gene mRNA related to lipid metabolism and synthesis in the mouse liver is reduced, the intestinal flora of the mouse is regulated, the obesity can be well improved, and the important application prospect in the preparation of the drugs or food for treating diabetes, reducing blood fat, obesity and non-alcoholic fatty liver disease is provided.

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

The invention discloses a preparation method of an edible flower phenol amide compound and application of the edible flower phenol amide compound in prevention and treatment of non-alcoholic fatty liver disease, and particularly relates to the field of development of new application of food raw materials. The edible flower phenol amide compound N1, N5, N10-coumaroyl spermidine (TCS) can be green extracted by using a natural deep-eutectic solvent (NADES), and can inhibit free fatty acid-induced liver cell lipid accumulation and improve fatty acid-caused liver cell fatty degeneration; oxidative stress and inflammation induced by free fatty acid are inhibited, and expression of senescence-related markers is inhibited, so that development of NAFLD is effectively inhibited.

The invention discloses an application of corilagin in preparation of a medicine for treating and / or preventing a non-alcoholic fatty liver disease. It is proved for the first time that corilagin can reduce lipid accumulation and inhibit oxidative stress through an Nrf2-ARE endogenous antioxidant pathway, has an obvious improvement effect on the non-alcoholic fatty liver disease, and it is proved that corilagin is expected to serve as an alternative medicine for treating the NAFLD, and the corilagin can be used as a medicine for treating the NAFLD. The potential application value is realized on the improvement and treatment of the NAFLD disease.

The invention discloses application of rutin hydrate in preventing and treating repeated embryo planting failure, and belongs to the technical field of assisted reproduction. It is found for the first time that CD36 is a key membrane protein for lipid transport and uptake of EECs, rutin hydrate competitively inhibits combination of CD36 and natural ligands of CD36, abnormal lipid excessive uptake is remarkably blocked, lipid accumulation and lipid toxicity damage in cells are effectively relieved, and the effect of inhibiting EECs lipid transport and uptake is achieved. And finally, the endometrial receptivity defect related to RIF is reversed, and the embryo adhesion and implantation capability is remarkably improved. Therefore, rutin hydrate provides a brand new strategy for developing targeted therapy drugs for RIF, especially for lipid metabolism disorder type endometrial receptivity badness, and has remarkable clinical application and transformation prospects.

The invention discloses application of a fucoidin degradation product Fuc-S in a pharmaceutical composition for preventing, relieving or treating type 2 diabetes mellitus and liver injury, and relates to the technical field of biological medicines. The invention provides a new effect of fucoidin Fuc-S in treating diabetic liver injury, and particularly, the fucoidin Fuc-S can significantly improve blood glucose control (reducing fasting blood glucose and enhancing sugar tolerance) and blood lipid spectrum (reducing TG, TC and LDL-C and increasing HDL-C) of diabetic mice, alleviate liver fatty degeneration and reduce serum ALT / AST level, and shows a significant liver protection effect. Furthermore, the Fuc-S can be used for remodeling the intestinal flora structure through specific enrichment of beneficial bacteria such as Bacteroides acdifaciens and the like, so that the generation of short-chain fatty acid (SCFAs) with a liver protection effect is promoted. The flora and metabolic change jointly improve the oxidative stress state of the liver, inhibit pro-inflammatory response and reduce lipid accumulation. The invention provides a novel nutrition intervention strategy for prevention and treatment of T2DM and liver complications thereof.

The present invention relates to an anti-obesity composition comprising a Geranium wilfordii extract. The extract according to the present invention exhibits an excellent body fat reduction effect by inhibiting lipid accumulation, and thus can be used in pharmaceutical and food fields as an anti-obesity composition.

The present invention aims to provide a novel pharmaceutical composition that can be used for the treatment or prevention of lysosomal storage diseases, particularly Niemann-Pick disease. [Solution] The present invention provides a pharmaceutical composition for the treatment or prevention of lysosomal storage diseases, characterized by containing a modified γ-cyclodextrin as an active ingredient, wherein the modified γ-cyclodextrin has a monovalent group derived from galacturonic acid that is bonded to a sugar residue of the γ-cyclodextrin via an amide bond.

The invention provides application of a xanthine derivative in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction, and belongs to the technical field of medicine preparation. The invention relates to an application of a xanthine derivative 8-[(2, 3-dihydroxy propyl) sulfo]-3-methyl-7-[(4-methylphenyl) methyl]-1H-purine-2, 6-diketone in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction. The xanthine derivative has dual efficacy of improving liver cell insulin sensitivity and / or reducing liver cell lipid accumulation, and provides a new way for treatment of metabolic dysfunction related fatty liver diseases and preparation of related clinical drugs.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

The invention relates to the technical field of biomedicine, in particular to application of an E3 ubiquitin enzyme inhibitor in non-alcoholic fatty liver related drugs. The TRIM23 has obvious influence on the non-alcoholic fatty liver disease, and hepatic cell lipid deposition induced by mixing of palmitic acid and oleic acid can be improved by inhibiting expression of the TRIM23 at the cellular level; on the contrary, promoting the expression level of the TRIM23 can aggravate hepatocyte lipid accumulation induced by mixing of palmitic acid and oleic acid. Therefore, the TRIM23 inhibitor can be used for preparing the medicine for preventing or treating the fatty liver.

This invention discloses a polypeptide with anti-wrinkle and oil-controlling effects, belonging to the field of cosmetic polypeptide technology. The polypeptide is heptapeptide-6, with the amino acid sequence Asn-Asp-Glu-Gly-Leu-Tyr-Leu. At concentrations of 0.001 mg / mL to 0.1 mg / mL, heptapeptide-6 significantly promotes the synthesis of type I collagen and elastin by human skin fibroblasts, exhibiting excellent anti-wrinkle and firming activity. At concentrations of 1 ppm to 50 ppm, it significantly inhibits lipid accumulation in *C. elegans* and lipid expression in zebrafish, with a maximum lipid inhibition rate of 24.38%, and also demonstrates clear oil-controlling activity. This invention's polypeptide has a single structure, overcoming the shortcomings of existing skincare polypeptides with single efficacy and complex formulations. It features stable processing, high safety, and is suitable as a core active ingredient in anti-wrinkle and oil-controlling cosmetics, providing a new avenue for the development and application of multifunctional skincare polypeptides.

The invention specifically discloses a novel chalcone compound as well as a preparation method, a pharmaceutical composition and application thereof. Experimental results show that the compound shows remarkable anti-inflammatory activity in a lipopolysaccharide stimulated RAW 264.7 cell model, and the anti-inflammatory activity is obviously superior to that of a positive drug dexamethasone; the compound shows a remarkable lipid accumulation inhibition effect in a HepG2 cell model treated by free fatty acid, is obviously superior to a positive drug obeticholic acid, and can be used for developing drugs for treating the non-alcoholic fatty liver disease, including but not limited to simple fatty liver, non-alcoholic steatohepatitis and related liver cirrhosis.

The invention discloses a novel medical application of Chiglitazar, Indeglitazar and LZ03, and belongs to the technical field of medicines. The invention relates to a novel medical application of Chiglitazar, Indeglitazar and LZ03. The new application of the medicine specifically refers to application of a PPAR universal agonist Chiglitazar, Indeglitazar, LZ03 or pharmaceutically acceptable salts thereof to preparation of a medicine for preventing and / or treating Duchenne muscular dystrophy, Duchenne muscular dystrophy skeletal muscle lipid ectopic deposition and Duchenne muscular dystrophy skeletal muscle aplastic disorder. The invention further relates to a preparation method of the medicine for preventing and / or treating the Duchenne muscular dystrophy skeletal muscle aplastic disorder and the application of the PPAR universal agonist Chiglitazar, Indeglitazar, LZ03 and the pharmaceutically acceptable salts thereof. It is proved for the first time that the three compounds can effectively improve core pathological injuries of Duchenne muscular dystrophy, relieve muscle fiber necrosis, skeletal muscle lipid accumulation and aplastic disorder, remarkably improve the skeletal muscle function, fill the application blank of the compounds in the field of Duchenne muscular dystrophy treatment, and have broad application prospects in treatment of Duchenne muscular dystrophy. A brand new candidate drug and a treatment thought are provided for prevention and / or treatment of Duchenne muscular dystrophy, and important clinical application value is achieved.

The invention discloses a pharmaceutical composition for improving glucose and lipid metabolism disorder by combining N-p-coumaroyl octoamine and rotundine and application of the pharmaceutical composition, and belongs to the field of biological medicine and metabolic disease treatment. In a db / db diabetic mouse model, it is found that NTPC (10 mg / kg) or ROT (10 mg / kg) single drugs can improve hyperglycemia and insulin resistance and reduce blood fat, and low-dosage combination (5 mg / kg of NTPC and 5 mg / kg of ROT) shows the most significant metabolism improvement effect which is obviously better than that of a single drug group. In an in-vitro fatty acid stimulation model, lipid accumulation in cells can be more remarkably reduced through combination of the two drugs, and fatty acid synthesis genes are inhibited.

The invention relates to the field of biological medicine, and discloses application of SCAP as a target spot in treatment or prevention of atherosclerosis. The invention proves that compared with normal control, SCAP expression of macrophages in aortic tissues of atherosclerosis patients is up-regulated. The invention proves that the progress of atherosclerosis can be obviously relieved by macrophage SCAP specific knockout. The invention also proves that macrophage SCAP specific knockout can improve aortic plaque lipid accumulation, and the local inflammation level is improved by influencing macrophage polarization to relieve atherosclerosis. According to the application, the application of the macrophage SCAP as a new target spot in treating or preventing the atherosclerosis is found.

The present application discloses a plant lactobacillus CCFM1366 capable of transforming various pueraria flavones and having the effects of alcoholism relieving and liver protecting, and a postbiotic prepared from the plant lactobacillus CCFM1366, and belongs to the technical field of microorganisms. The plant lactobacillus CCFM1366 and the postbiotic prepared from the plant lactobacillus CCFM1366 have at least one of the following effects: (1) improving alcohol metabolism enzyme activity and enhancing alcohol metabolism; (2) improving liver steatosis, lipid accumulation, oxidative stress and inflammatory response caused by long-term alcohol exposure; (3) reducing ROS synthesis and thereby reducing oxidative damage to liver cells, promoting the synthesis of antioxidants and thereby improving the protective effect on liver cells; and (4) reducing inflammatory response. The plant lactobacillus CCFM1366 and the postbiotic prepared from the plant lactobacillus CCFM1366 can be used for preparing functional food and / or dietary supplements with the potential of alcoholism relieving and liver protecting, and have great application prospect.

The invention discloses a mesenchymal stem cell preparation and application thereof, and belongs to the technical field of cell biology. The mesenchymal stem cell preparation is a mesenchymal stem cell pretreated by a combined drug of ziyuglycoside II and shikonin. Through drug pretreatment, the antioxidant capacity of the mesenchymal stem cells is synergistically enhanced, the survival rate of the cells after transplantation is enhanced, the treatment effect of the cells on the NAFLD hepatocytes is remarkably enhanced, and lipid accumulation in the hepatocytes is effectively reduced. Therefore, the invention provides a novel method for enhancing the treatment capacity of the mesenchymal stem cells NAFLD, the method is suitable for bone marrow and umbilical cord mesenchymal stem cells, and an efficient and reliable preparation and an optimization scheme are provided for clinical stem cell treatment of the NAFLD.

The application relates to the technical field of biological processing, and discloses a ganoderma heteroterpene derivative with antioxidant and blood lipid-lowering activities and a preparation method thereof, which comprises the following steps: using methanol to dissolve Ganoderma capense ethyl acetate extract and mixing with silica gel; 10 components of crude components Fr.1-Fr.10 are obtained, and a compound one is separated; Fr.5 components are selected and a compound three is prepared; Fr.9 components are selected to carry out silica gel column chromatography and a compound two is separated; the ganoderma heteroterpene derivative with antioxidant and blood lipid-lowering activities and the preparation method thereof can reverse the trend that the MDA content in tissues is increased and the GPX activity is decreased after high-fat diet is taken due to lipid accumulation and increased lipid peroxidation, can realize lipid-lowering activity, and is easy to prepare from raw materials and suitable for popularization and use.

The invention belongs to the field of medicines, and particularly discloses application of ImP (Imidazole Propionic Acid) in preparation of medicines for preventing or treating metabolic syndrome related diseases, aiming at the problems that the existing anti-obesity medicines are large in side effect, limited in curative effect and the like, and metabonomics research finds that the peripheral blood ImP level in a high-fat diet induced obesity model is remarkably reduced. A zebra fish model (250 [mu] M) and a human fat cell experiment (10-1000 [mu] M) prove that ImP significantly reduces the lipid accumulation rate by more than 40% (Plt; 0.01) of the substrate. The pharmaceutical composition can be prepared into dosage forms such as oral tablets (for example, each tablet containing 50 mg of ImP), sustained-release injections and the like, and can be theoretically combined with orlistat and other medicines for use. Compared with the traditional therapy, the invention reveals the lipid metabolism regulation function of ImP for the first time, and the ImP has the advantages of strong targeting property (IC50 = 120 mu M), high safety (LD50gt; 2000mg / kg) and the like, and a brand new microbial metabolite intervention strategy is provided for obesity and related metabolic diseases.

The invention belongs to the technical field of medicines, and particularly relates to application of urolithin A and beta-nicotinamide mononucleotide in preparation of a medicine for treating diabetes. The invention finds that when the urolithin A and the beta-nicotinamide mononucleotide are independently used, the hypoglycemic effect on diabetic mice cannot be realized, and when the urolithin A and the beta-nicotinamide mononucleotide are jointly used, the symptoms of diabetes and insulin resistance caused by high fat diet can be remarkably improved; the glucose tolerance and the insulin tolerance are improved; meanwhile, the content of low-density lipoprotein and cholesterol in a mouse body is reduced, so that the risk of thrombus occurrence is reduced; in addition, combined medication can significantly reduce liver cell lipid accumulation and improve mitochondrial morphological abnormality. The invention provides a brand new technical scheme and experimental basis for treating diabetes caused by high fat diet and relieving insulin resistance, and has important medical application value.

The invention relates to application of cepharanthine in preparation of medicines for preventing or treating metabolic dysfunction related fatty liver diseases (Metabolic-associated fatty liver diseases), and particularly relates to application of cepharanthine in preparation of medicines for preventing or treating metabolic dysfunction related fatty liver diseases (Metabolic-associated fatty liver diseases). The invention relates to an application of MASLD in a medicine, and belongs to the technical field of biological medicines. In an in-vivo experiment, a mouse MASLD model is established by adopting methionine choline deficiency diet induction, and the treatment effect of cepharanthine on MASLD is researched. Experimental results show that the cepharanthine can significantly reduce the levels of triglyceride, glutamic-pyruvic transaminase, glutamic oxalacetic transaminase and other indexes of MASLD mice; a pathological detection result shows that cepharanthine can effectively reduce liver lipid deposition and inflammatory infiltration. In-vitro experiments prove that cepharanthine can effectively reduce the content of free fatty acid (Free Fatty Acid); fFA (Fatty Acid) induced HepG2 (HepG2) cell lipid accumulation and lipopolysaccharides (lipopolysaccharides) induced HepG2 cell lipid accumulation and lipopolysaccharides (FFA) induced HepG2 cell lipid accumulation; the THP-1 cell inflammatory response is induced by LPS (Lipopolysaccharide). In conclusion, the cepharanthine shows remarkable anti-lipid accumulation and anti-inflammatory effects in in-vivo and in-vitro experiments, can be used for preparing the medicine for preventing or treating MASLD, and has a wide application prospect.

The invention relates to an application of oligosporine in preparation of a weight-reducing medicine. The invention finds that the oligosporine B can reduce the weight of mammals. Moreover, the further research finds that the weight loss of mammals can be realized due to the fact that triglyceride in fat cells is hydrolyzed into free fatty acid and glycerol by mainly enhancing the activity of a key rate-limiting enzyme responsible for lipid metabolism in the fat cells so as to reduce the blood fat level and lipid accumulation in the fat cells, so that the weight loss of the mammals can be realized. Therefore, the weight loss is realized by reducing the adipose tissue mass.

The present invention provides a basis for using soluble fiber, particularly compositions comprising Agave fructans, to prevent or treat the accumulation of lipids, particularly ceramides in the liver and brain and lipofuscin in the liver, improving the overall integrity of both organs, with treatment being feasible to prevent fatty liver disease and also prevent Alzheimer's disease (AD). In the present invention, we analyze alterations in lipid metabolism in the liver and ceramide production in the brain of transgenic mice (APP / PS1, TG) for AD. Our results indicate that microvesicular lipid accumulation within hepatocytes is increased in TG mice compared to the control group. Furthermore, in the brains of TG mice, a greater accumulation of ceramides is observed in the somatosensory cortex and entorhinal cortex; in the CA1 region of the hippocampus and in the motor cortex, no significant increase was observed when compared to the control group.

This invention discloses a fish-derived bioactive peptide with dual functions of enhancing saltiness and inhibiting adipocyte differentiation, and its applications, belonging to the field of biotechnology. The bioactive peptide is a γ-glutamylarginine peptide with the general formula γ-[Glu]n-Arg, where n is an integer from 1 to 4. This invention efficiently prepared a series of γ-[Glu]n-Arg peptides through a targeted enzymatic synthesis method, further elucidating the dual effects of this bioactive peptide at the molecular mechanism level. The bioactive peptide can effectively enhance saltiness perception by binding to the saltiness receptor TMC4, and inhibit adipocyte differentiation and reduce lipid accumulation through multiple targets by downregulating PPAR-γ, C / EBPα, and FAS genes, and upregulating AMPK and HSL genes. This invention provides a reliable scientific basis and technical support for developing innovative food ingredients with both flavoring and health functions.

The invention belongs to the technical field of comprehensive utilization of oyster mushrooms, and provides an oyster mushroom active peptide for inhibiting foaming of macrophages and a preparation method of the oyster mushroom active peptide. The method comprises the following steps: taking oyster mushroom as a raw material, preparing oyster mushroom protein through alkali extraction and acid precipitation, preparing a crude product of the oyster mushroom active peptide for inhibiting foaming of macrophages through compound enzymatic hydrolysis of the oyster mushroom protein by pepsin, trypsin and chymotrypsin, and separating and purifying the crude product by adopting ultrafiltration membrane ultrafiltration and Sephadex G-15 gel column chromatography to obtain the peptide with good activity and high purity. The bioactive peptide can reduce lipid accumulation, ROS level, TNF-alpha content and IL-6 content in RAW264.7 foamed macrophages, and effectively improve lipid accumulation, oxidative stress and inflammatory state of the foamed macrophages, thereby inhibiting foaming of the macrophages.

The invention discloses application of pseudo-ginseng external vesicles in preparation of drugs for preventing or improving fatty liver diseases. Researches find that the pseudo-ginseng external vesicles can significantly reduce the levels of total cholesterol, triglyceride, asparaginic acid aminotransferase and alanine aminotransferase, down-regulate expression of fat synthesis related genes and inflammatory factors, improve lipid accumulation caused by fatty liver diseases, reduce body weight and liver-to-weight ratio, repair pathological damage of liver tissues and the like.

This invention belongs to the field of traditional Chinese medicine and discloses the application of total saponins extract of *Abrus precatorius* in the preparation of drugs for treating metabolic-associated fatty liver disease (MAFLD). Through experiments in high-fat diet-induced MAFLD mice, this invention demonstrates that total saponins of *Abrus precatorius* can protect the liver from a series of damages caused by excessive lipid accumulation. The potential mechanisms include regulating lipid metabolism through the PPAR and AMPK signaling pathways, and modulating the balance of gut microbiota. These findings provide a solid research foundation and empirical evidence for the potential application of total saponins of *Abrus precatorius* in the treatment of MAFLD.